MLYS
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Mineralys Therapeutics received FDA acceptance of its NDA for lorundrostat to treat hypertension and reported Explore-OSA trial resultsMar 10, 2026
- Mineralys Therapeutics announces late-breaking presentation of Phase 2 Explore-CKD trial of Lorundrostat at American Society of Nephrology Kidney Week 2025Oct 21, 2025
- Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial of Lorundrostat in obstructive sleep apnea and hypertensionSep 30, 2025
- Mineralys Therapeutics presents subgroup analyses of Phase 3 Launch-HTN trial demonstrating efficacy and safety of Lorundrostat in hypertension patients with high unmet medical needSep 8, 2025